In support of this hypothesis, patients with other genetic syndromes resulting in increased MAPK pathway activation, such as Noonen’s [9], tuberous sclerosis (TSC) [10, 11], or SYNGAP1 deficiency [12], have an increased incidence of epilepsy [11, 13, 14]. This evidence concerns the gene SYNGAP1 and tuberous sclerosis.